ArticleJournal of clinical medicine2024

Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel.

Shao-Jing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.